一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法规、部门规 童及其他规范性文件,具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 科创板上市公司独立董事候选人声明与承诺 本人郑佳宁,已充分了解并同意由提名人北京莱伯泰科仪器股份有限公司董 事会提名为北京莱伯泰科仪器股份有限公司第五届董事会独立董事候选人。本人 公开声明,本人具备独立董事任职资格,保证不存在任何影响本人担任北京莱伯 泰科仪器股份有限公司独立董事独立性的关系，具体声明并承诺如下: (二)《中华人民共和国公务员法》关于公务员兼任职务的规定(如适用); (三)中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定; (四)中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 (离)休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用): 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： (一)《中华人民共和国公司法》等关于董事任职资格的规定; (五)中共中央组织部《关于进一步规范党政领导干部在企业兼职(任职) 问题的意见 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-011 北京莱伯泰科仪器股份有限公司 关于向全资子公司增资的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 增资标的公司名称：LabTech,Inc.(以下简称"莱伯泰科美国") 增资金额及资金来源：公司拟以自有资金向全资子公司莱伯泰科美国进 行增资，增资金额为 400.00 万美元。 本次增资事项已经公司第四届董事会第十六次会议审议通过，无需提交 公司股东会审议。 2025 年 4 月 24 日，公司第四届董事会第十六次会议审议通过了《关于向全 资子公司增资的议案》，同意公司以自有资金 400.00 万美元向莱伯泰科美国进行 增资，并授权公司管理层及其授权人士办理本次增资的各项具体工作。本次增资 事项在公司董事会权限范围内，无需提交公司股东会审议。本次增资事项尚需相 关部门审批或备案。 （三）不属于关联交易和重大资产重组事项说明 本次增资事项不构成《上海证券交易所科创板股票上市规则》和《公司章程》 规定的关联交易，也不构成《上市公司重大资 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-014 北京莱伯泰科仪器股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2024年年度股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 16 日 13 点 30 分 召开地点：北京市顺义区空港工业区 B 区安庆大街 6 号北京莱伯泰科仪器 股份有限公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 16 日 至2025 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2025年5月16日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-016 北京莱伯泰科仪器股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京莱伯泰科仪器股份有限公司（以下简称"公司"）第四届监事会第十五次会议通 知于 2025 年 4 月 11 日以书面形式发出，并于 2025 年 4 月 24 日在公司会议室以现场与 通讯相结合的方式召开。本次会议应到监事 3 人，实到监事 3 人。 本次会议由监事会主席王争奇先生召集并主持。会议的召开符合法律、行政法规、 部门规章和《北京莱伯泰科仪器股份有限公司章程》（以下简称"《公司章程》"）的规定， 合法有效。 二、监事会会议审议情况 经与会监事认真审议，会议形成了如下决议： （一）审议通过《关于公司<2024 年年度报告>及其摘要的议案》 经审议，公司监事会认为公司《2024 年年度报告》的编制和审议程序符合法律、法 规、《公司章程》和公司内部管理制度的各项规定；公司《2024 年年度报告》内容和格 式符合中 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-015 北京莱伯泰科仪器股份有限公司 第四届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京莱伯泰科仪器股份有限公司（以下简称"公司"）第四届董事会第十六 次会议通知于 2025 年 4 月 11 日以书面形式发出，并于 2025 年 4 月 24 日在公司 会议室以现场与通讯相结合的方式召开。会议应出席董事 7 人，实际出席董事 7 人。公司监事和高级管理人员列席了会议。 会议由董事长胡克先生召集并主持。会议的召开符合有关法律、行政法规、 部门规章和《北京莱伯泰科仪器股份有限公司章程》（以下简称"《公司章程》"） 的规定，合法有效。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： （一）审议通过《关于公司<2024 年年度报告>及其摘要的议案》 经审议，董事会同意公司报出《2024 年年度报告》及其摘要。公司董事会 认为公司《2024 年年度报告》的编制和审议程序符合法律、法规、《公司 ...

北京莱伯泰科仪器股份有限公司 证券代码：688056 证券简称：莱伯泰科 公告编号：2025-005 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利 6.00 元（含税），不进行资本 公积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购 专用证券账户中股份为基数，具体日期将在权益分派实施公告中明确。在实施权 益分派的股权登记日前公司总股本发生变动的，公司拟维持每股分配比例不变， 相应调整分配总额，并将另行公告具体调整情况。 本次利润分配方案已经公司第四届董事会第十六次会议审议通过，尚 需提交公司股东会审议。 一、 利润分配方案内容 （一）利润分配方案的具体内容 经信永中和会计师事务所（特殊普通合伙）审计，北京莱伯泰科仪器股份有 限公司（以下简称"公司"）2024 年度实现归属于上市公司股东的净利润为人 民币 39,148,080.18 元，截至 2024 年 12 月 31 日，公司期末合并报表未分配利 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-009 北京莱伯泰科仪器股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 关于作废部分已授予尚未归属的限制性股票的公告 北京莱伯泰科仪器股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开第四届董事会第十六次会议、第四届监事会第十五次会议，审议通过了《关于 作废部分已授予尚未归属的限制性股票的议案》。现将相关事项公告如下： 一、激励计划已履行的决策程序 （一）2022 年 12 月 27 日，公司召开第四届董事会第四次会议，审议通过 了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2022 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请公 司股东大会授权董事会办理 2022 年限制性股票激励计划相关事宜的议案》等议 案。公司独立董事就本激励计划相关议案发表了独立意见。 同日，公司召开第四届监事会第四次会议，审议通过了《关于公司<2022 年 限制性股票激励计划（草案）>及其摘要的议 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥99,050,789.19, a decrease of 6.09% compared to ¥105,478,954.63 in the same period last year[4] - Net profit attributable to shareholders increased by 10.30% to ¥12,766,699.84 from ¥11,574,778.68 year-on-year[4] - The basic earnings per share rose by 11.76% to ¥0.19, compared to ¥0.17 in the previous year[4] - Total operating revenue for Q1 2025 was ¥99,050,789.19, a decrease of 6.8% compared to ¥105,478,954.63 in Q1 2024[19] - Net profit for Q1 2025 increased to ¥12,766,699.84, up 10.3% from ¥11,574,778.68 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.19, compared to ¥0.17 in Q1 2024[21] - The company reported a total comprehensive income of ¥12,278,853.46 for Q1 2025, an increase from ¥11,698,038.01 in Q1 2024[21] Research and Development - Research and development expenses totaled ¥11,358,075.06, down 8.02% from ¥12,347,788.06, with R&D expenses accounting for 11.47% of operating revenue, a decrease of 0.24 percentage points[5] - Research and development expenses for Q1 2025 were ¥11,358,075.06, down from ¥12,347,788.06 in Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥3,144,132.03, compared to -¥1,282,305.88 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was negative at -¥3,144,132.03, worsening from -¥1,282,305.88 in Q1 2024[23] - Net cash flow from financing activities was -314,223.38, indicating a significant outflow[24] - The net increase in cash and cash equivalents was -31,930,462.23, reflecting a decrease in liquidity[24] - The ending balance of cash and cash equivalents was 254,655,508.23, down from the beginning balance of 286,585,970.46[24] - The impact of exchange rate changes on cash and cash equivalents was 66,272.80, showing some resilience against currency fluctuations[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥954,742,314.35, a slight decrease of 0.10% from ¥955,712,276.45 at the end of the previous year[5] - The company's current assets totaled CNY 770,603,668.73, compared to CNY 767,512,121.41 at the end of 2024, indicating a growth of approximately 0.27%[14] - The total liabilities decreased from CNY 138,123,645.32 to CNY 124,462,990.38, reflecting a reduction of about 9.87%[15] - The cash and cash equivalents were reported at CNY 256,033,636.45, down from CNY 288,549,367.12, representing a decline of approximately 11.3%[13] - Accounts receivable increased to CNY 59,858,827.85 from CNY 55,096,497.57, showing an increase of about 8.5%[14] - Inventory levels slightly rose to CNY 171,127,708.48 from CNY 170,415,498.94, indicating a marginal increase of 0.42%[14] - The company reported a significant increase in accounts payable from CNY 39,600,301.87 to CNY 47,945,740.77, which is an increase of approximately 20.5%[15] - The total equity remained stable at CNY 67,452,460.00, unchanged from the previous reporting period[15] Shareholder Information - The net assets attributable to shareholders increased by 1.55% to ¥830,279,323.97 from ¥817,588,631.13 at the end of the previous year[5] - The total number of ordinary shareholders at the end of the reporting period was 3,085[10] - The company's total equity attributable to shareholders increased to ¥830,279,323.97 from ¥817,588,631.13 year-over-year[16] Government Support and Future Outlook - The company received government subsidies amounting to ¥90,935.08, which are expected to have a continuous impact on profits[6] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[12] - The company will not apply new accounting standards starting from 2025, maintaining current reporting practices[24]

Financial Performance - The company's operating revenue for 2024 reached CNY 424.01 million, a year-on-year increase of 1.93%[19]. - Net profit attributable to shareholders for 2024 was CNY 39.15 million, representing a significant increase of 42.03% compared to the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 30.96 million, up 32.88% year-on-year[19]. - The company's cash flow from operating activities increased by CNY 12.55 million, aligning with the growth trend of net profit[21]. - Basic and diluted earnings per share for 2024 were CNY 0.59, a 43.90% increase compared to the previous year[21]. - The net cash flow from operating activities increased by 29.47% to 55.15 million RMB, reflecting improved operational performance[127]. - The company reported a total revenue of 8,580.00 million RMB, with a net profit of 2,134.47 million RMB, representing a year-on-year increase of 5,551.36 million RMB[104]. Dividend and Share Capital - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares (including tax), totaling approximately 40,066,942.80 RMB, which represents 102.35% of the net profit attributable to shareholders for the year 2024[5]. - As of December 31, 2024, the total share capital is 67,452,460 shares, with 674,222 shares in the repurchase account, resulting in 66,778,238 shares eligible for profit distribution[5]. Research and Development - The proportion of R&D investment to operating revenue was 12.09%, a slight decrease of 0.46 percentage points from the previous year[21]. - Research and development expenses amounted to 51.27 million RMB, accounting for 12.09% of operating revenue[35]. - The company has obtained 19 new authorized patents and 3 new software copyrights during the reporting period, totaling 143 authorized patents and 76 software copyrights[39]. - The company has developed a solid-phase extraction automation platform that is widely used in biological analysis and proteomics research[104]. - The company aims to strengthen its R&D capabilities and product technology levels to maintain competitiveness in the high-end instrument market[40]. Product Development and Innovation - The company successfully launched the LabMS 5000 ICP-MS/MS product, which was included in the "Beijing 2024 Major Technical Equipment Directory" for the medical and health sector[32]. - The company launched the AutoEmpore fully automatic rapid solid-phase extraction instrument, enhancing water sample pretreatment technology[39]. - The company plans to release the I-Lab 180 fully automatic iodine analyzer in September 2024, responding to public health system needs and showcasing its R&D capabilities[74]. - The company has developed multiple sample pretreatment instruments that can directly connect with analytical testing instruments, improving analysis efficiency and accuracy[79]. - The company is focusing on the development of technologies that integrate sample pre-treatment instruments with analytical instruments, enhancing overall workflow efficiency[89]. Market and Industry Trends - The total revenue for the inspection and testing industry reached 467.009 billion yuan in 2023, representing a year-on-year growth of 9%[45]. - The market for experimental analysis instruments is expected to grow due to increasing demand in downstream applications such as environmental monitoring and food safety[72]. - The company is focusing on the development of new analysis instruments and sample pretreatment products, aiming to enhance market share in traditional fields while expanding into new sectors such as renewable energy and biomedicine[75]. - The company aims to enhance detection precision, efficiency, and safety by improving instrument performance and analysis technology[45]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[4]. - The company has a strong internal control system and has not identified any significant internal control deficiencies during the reporting period[46]. - The company has not reported any special arrangements for corporate governance[7]. - The company has retained its accounting firm for the upcoming fiscal year as part of its governance strategy[184]. Risks and Challenges - The company faces risks related to product development failures, which could impact its technological advantages and long-term growth[116]. - The company is exposed to foreign exchange risks due to its import and export activities, particularly with USD and EUR transactions[123]. - The company must navigate macroeconomic fluctuations and changes in national policies that could affect its operations[125]. Strategic Initiatives - The company plans to enhance its brand promotion through a combination of online and offline strategies, focusing on emerging industries and market segments[43]. - The company aims to provide customized solutions by integrating sample pretreatment and analytical testing instruments, shifting from traditional sales models[86]. - The company plans to improve its product line by developing new technologies and products, including mobile detection instruments and sample pretreatment products, to meet diverse customer needs[173].

北京莱伯泰科仪器股份有限公司 2024 年度 内部控制审计报告 索引 页码 内部控制审计报告 1-2 联系申话: 信永中和会计师事务所| 北京市东城区朝阳门北大街 telephone: 8 号富华大厦 A 座 9 层 +86 (010) 6554 2288 +86 (010) 65 blic accountants 北京莱伯泰科仪器股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计 了北京莱伯泰科仪器股份有限公司(以下简称莱伯泰科公司)2024年12月31日财务报 告内部控制的有效性。 一、企业对内部控制的责任 9/F. Block A. Fu Hua Mansion No.8. Chaovangmen Beidaiie Donachena District. Beijin 100027. P.R.China +86 (010) 6554 7190 内部控制审计报告 XYZH/2025BJAA2B0240 北京莱伯泰科仪器股份有限公司 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定,建立健全和有效实施内部控制,并评价其有效 ...